Without digging deeper , the PR doesn't give enough info to say whether this is a signif advance over BNP and NT-proBNP testing. Indeed, the PR doesn't even say whether the two tests have gone head to head in a trial.
There sure doesn't seem to be any likelihood of near term good news priced into Response the way it is trading lately.
News 
Market Data 
Discover 
